5.5 Oral Anticoagulants, Antiplatelets & Peri-Procedural Management
Key Takeaways
- CHA2DS2-VASc assigns 2 points each for age 75 or older and prior stroke or TIA, and 1 point each for heart failure, hypertension, age 65-74, diabetes, vascular disease, and female sex.
- Ablation is performed on uninterrupted warfarin with an INR of 2.0-3.0 or on a minimally interrupted DOAC, because interrupted anticoagulation with heparin bridging increases both bleeding and thromboembolism.
- Idarucizumab reverses dabigatran and andexanet alfa reverses apixaban and rivaroxaban; four-factor prothrombin complex concentrate plus vitamin K reverses warfarin.
- Anticoagulation continues for at least 2-3 months after ablation regardless of rhythm, and long-term continuation is decided by CHA2DS2-VASc rather than by procedural success.
- A transesophageal echocardiogram or cardiac CT excludes left atrial appendage thrombus when anticoagulation has been subtherapeutic or interrupted before a left-sided procedure.
5.5 Oral Anticoagulants, Antiplatelets & Peri-Procedural Management
Intra-procedural heparin is only half of the anticoagulation picture. Patients arrive in the EP lab already taking an oral anticoagulant, an antiplatelet agent, or both, and the decisions made before the case begins drive both stroke risk and bleeding risk.
1. Stroke and Bleeding Risk Scoring
CHA₂DS₂-VASc
| Letter | Factor | Points |
|---|---|---|
| C | Congestive heart failure / LV dysfunction | 1 |
| H | Hypertension | 1 |
| A₂ | Age ≥ 75 | 2 |
| D | Diabetes mellitus | 1 |
| S₂ | Prior Stroke / TIA / thromboembolism | 2 |
| V | Vascular disease (prior MI, PAD, aortic plaque) | 1 |
| A | Age 65-74 | 1 |
| Sc | Sex category (female) | 1 |
| Maximum | 9 |
The two 2-point items — age ≥ 75 and prior stroke/TIA — are the most commonly missed detail. Anticoagulation is generally recommended at a score of ≥ 2 in men and ≥ 3 in women, and considered at 1 and 2 respectively; female sex alone does not drive treatment.
Worked example. A 78-year-old woman with hypertension, diabetes, and a prior TIA: age ≥ 75 (2) + hypertension (1) + diabetes (1) + prior TIA (2) + female (1) = 7. This is a high-risk patient in whom anticoagulation is not optional and in whom pre-procedural imaging matters if therapy has lapsed.
HAS-BLED
Hypertension (uncontrolled), Abnormal renal or liver function (1 each), Stroke, Bleeding history or predisposition, Labile INR, Elderly (> 65), Drugs (antiplatelets, NSAIDs) or alcohol (1 each) — maximum 9. A score ≥ 3 flags high bleeding risk. Critically, HAS-BLED identifies modifiable risk factors to correct; it is not a reason to withhold anticoagulation in a patient who needs it.
2. The Agents
| Drug | Class / target | Onset | Half-life | Monitoring | Renal clearance |
|---|---|---|---|---|---|
| Warfarin | Vitamin K antagonist (factors II, VII, IX, X, protein C and S) | 3-5 days for full effect | 36-42 h | INR 2.0-3.0 | Hepatic |
| Dabigatran | Direct thrombin (IIa) inhibitor | 1-3 h | 12-17 h | None routine | ~80% renal |
| Rivaroxaban | Factor Xa inhibitor | 2-4 h | 5-13 h | None routine | ~33% renal |
| Apixaban | Factor Xa inhibitor | 3-4 h | ~12 h | None routine | ~27% renal |
| Edoxaban | Factor Xa inhibitor | 1-2 h | 10-14 h | None routine | ~50% renal |
Two clinically load-bearing facts: warfarin's slow onset means it cannot be started and relied upon within days, and its early effect is paradoxically procoagulant because protein C falls before factor II. Dabigatran's heavy renal clearance means that in acute kidney injury its effect accumulates dramatically.
Antiplatelets: aspirin irreversibly inhibits COX-1 for the platelet's 7-10 day life; clopidogrel, prasugrel, and ticagrelor block the P2Y12 receptor (ticagrelor reversibly). Dual antiplatelet therapy plus an anticoagulant markedly increases bleeding and is minimized in duration wherever possible.
3. Peri-Procedural Strategy
The strategy differs by procedure type, and the exam tests the distinctions.
Catheter ablation of atrial fibrillation
| Strategy | Practice | Evidence |
|---|---|---|
| Uninterrupted warfarin | Continue through the procedure with INR 2.0-3.0 on the day | Lower thromboembolism and lower major bleeding than bridged interruption |
| Uninterrupted or minimally interrupted DOAC | Continue, or hold one dose the morning of the procedure and resume the same evening | Comparable safety to uninterrupted warfarin |
| Heparin bridging after interruption | Avoided | Increases bleeding without reducing stroke |
Intra-procedural heparin is given at or immediately before transseptal puncture with an ACT target of 300-350 seconds in the left atrium.
CIED implantation
The landmark finding here is counterintuitive and frequently tested: for patients at moderate-to-high thromboembolic risk, continuing warfarin through device implantation produces far fewer clinically significant pocket hematomas than interrupting it and bridging with heparin. Bridging is therefore avoided. DOACs are commonly held for one to two doses around implantation depending on renal function and bleeding risk.
Pre-procedural imaging
A transesophageal echocardiogram (or cardiac CT) is obtained before left atrial ablation or LAA closure when anticoagulation has been interrupted, subtherapeutic, or of uncertain duration; when atrial fibrillation has persisted beyond 48 hours without documented anticoagulation; or when thromboembolic risk is high. A detected appendage thrombus cancels the procedure and mandates several weeks of therapeutic anticoagulation with repeat imaging.
Renal dosing
DOAC dose reduction depends on creatinine clearance and drug-specific criteria — apixaban is reduced when two of three are present (age ≥ 80, weight ≤ 60 kg, creatinine ≥ 1.5 mg/dL), and dabigatran is contraindicated at severely reduced clearance. A patient whose renal function has deteriorated since the last clinic visit may be far more anticoagulated than the chart suggests.
4. Reversal
| Agent | Reversal | Notes |
|---|---|---|
| Warfarin | Vitamin K (slow, hours) plus 4-factor prothrombin complex concentrate (immediate) | Fresh frozen plasma is an alternative when PCC is unavailable, at a large volume cost |
| Dabigatran | Idarucizumab — a monoclonal antibody fragment | Rapid and specific; dialysis also removes dabigatran |
| Apixaban / rivaroxaban | Andexanet alfa — a modified decoy factor Xa | 4-factor PCC is used when andexanet is unavailable |
| Unfractionated heparin | Protamine sulfate, 1 mg per 100 units of active heparin | Slow IV; anaphylactoid risk with NPH insulin exposure, prior vasectomy, or fish allergy |
| Low molecular weight heparin | Protamine, partial reversal only (~60%) | Anti-Xa activity is incompletely neutralized |
| Antiplatelets | No specific reversal | Platelet transfusion for life-threatening bleeding |
5. After the Procedure
The post-ablation rule is one of the most reliably tested facts in EP:
- Anticoagulation continues for a minimum of 2 to 3 months after ablation regardless of the rhythm on the monitor. The ablated atrium is denuded and inflamed, and post-cardioversion atrial stunning impairs mechanical function even when electrical sinus rhythm is restored.
- Beyond that window, continuation is decided by CHA₂DS₂-VASc, not by whether the ablation appears successful. A patient with a score of 4 who is in sinus rhythm at three months still requires anticoagulation, because asymptomatic recurrence is common and the score reflects underlying stroke risk.
- Patients frequently ask to stop therapy once symptoms resolve; the correct counselling is that symptom resolution is not evidence of arrhythmia elimination.
After left atrial appendage closure, a device-specific regimen — anticoagulation or dual antiplatelet therapy for a defined interval, followed by imaging to confirm seal and absence of device-related thrombus, then a step-down to aspirin — replaces indefinite anticoagulation.
A 79-year-old woman with hypertension, type 2 diabetes, heart failure with reduced ejection fraction, and a prior transient ischemic attack is scheduled for pulmonary vein isolation. What is her CHA2DS2-VASc score?
A patient at moderate thromboembolic risk on chronic warfarin is scheduled for dual-chamber pacemaker implantation. Which peri-procedural anticoagulation strategy is best supported?
Three months after successful pulmonary vein isolation, a patient with a CHA2DS2-VASc score of 4 has had no symptomatic recurrence and a normal 14-day monitor. He asks to stop his rivaroxaban. What is the correct counselling?